Immunovant, INC. (IMVT) — 10-Q Filings

10-Q Filings (5)

• Immunovant Q1: No Revenue, Focus on Pipeline Development — Aug 11, 2025 Risk: high
  Immunovant, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its prior-year period, as it remains a clinical-stage biopharmaceutica
• Immunovant Files 10-Q for Q3 FY2025 — Feb 6, 2025 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the three and nine months ended December 31, 2024, and compares them
• Immunovant, Inc. Files 10-Q for Q3 2024 — Nov 7, 2024 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operat
• Immunovant Files 10-Q for Q2 2024 — Aug 6, 2024 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations.
• Immunovant, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 12, 2024 Risk: low
  Immunovant, Inc. (IMVT) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Immunovant, Inc. reported its Q3 2024 financial results. The company'

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX